Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Gerald Naccarelli

Pennsylvania State University

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States

Articles (12)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Harry Crijns

Maastricht University Medical Centre

NETHERLANDS

View details

Carina Blomström-Lundqvist

Senior consultant, Professor

Uppsala University

SWEDEN

View details

Dobromir Dobrev

Universität Duisburg-Essen

GERMANY

View details

Juan Tamargo

Catedrático de Universidad

Universidad Complutense de Madrid

SPAIN

View details

José L Merino

La Paz University Hospital

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gerald Naccarelli

Research Interests

Make your next move.

Explore related searches

Articles (12)

The Brugada Syndrome: Is Provocative Testing Necessary?

Do clinical trials adequately serve clinical practitioners?

Left Ventricular Global Longitudinal Strain Is Associated With Appropriate Therapies for Ventricular Arrhythmias Independent of Left Ventricular Ejection Fraction in Patients With Primary Prevention Defibrillators

Which Patient Benefits from Guideline-directed Medical Therapy for Heart Failure and Rate Control versus Rhythm Control in Patients with Congestive Heart Failure and Atrial Fibrillation and What are Those Therapies?

Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology

Cancer Patients With Atrial Fibrillation Need More Aggressive Treatment to Prevent Stroke

Aggressive treatment of atrial fibrillation in hypertrophic cardiomyopathy patients improve quality of life

Antiarrhythmic Drug Therapy: Where Do We Go From Here?

Can Risk Stratification Scores Improve Selection Of Patients Who Need Primary Prevention Implantable Cardioverter-Defibrillators Or Should We Just Follow The Rules?

Direct Oral Anticoagulants: Patients Benefit When Prescribers Get the Message

Are Class IC Antiarrhythmic Agents Safe in Atrial Fibrillation Patients With Nonobstructive Coronary Artery Disease?

Should we limit antiarrhythmic drug choice in patients with left ventricular hypertrophy?

Collaborators (5)

Harry Crijns

Carina Blomström-Lundqvist

Dobromir Dobrev

Juan Tamargo

José L Merino

Make your next move.